Advanced in Immune Thrombocytopenic Purpura (ITP)

Dr. Roger M. Lyons

Hematology | Oncology
Texas Oncology PA
2026 S Jackson St, 
Jacksonville, TX 
Accepting New Patients
Offers Telehealth
Advanced in Immune Thrombocytopenic Purpura (ITP)
Texas Oncology PA
2026 S Jackson St, 
Jacksonville, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roger Lyons is a Hematologist and an Oncologist in Jacksonville, Texas. Dr. Lyons is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Myelodysplastic Syndrome (MDS), Idiopathic Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Splenectomy. Dr. Lyons is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Immune Thrombocytopenic Purpura (ITP).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
2026 S Jackson St, Jacksonville, TX 75766

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

43 Total Publications

A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis.
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis.
Journal: Leukemia research
Published: January 29, 2025
Similar Doctors
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Praveen K. Tumula
Hematology Oncology | Oncology | Hematology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Praveen K. Tumula
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

2026 S Jackson St, 
Jacksonville, TX 
 (0.1 miles away)
903-586-2456
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Praveen Tumula is a Hematologist Oncology specialist and an Oncologist in Jacksonville, Texas. Dr. Tumula is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Subacute Combined Degeneration, Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Tumula is currently accepting new patients.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Michael Y. Ashigbi
Hematology Oncology | Hematology | Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Michael Y. Ashigbi
Hematology Oncology | Hematology | Oncology
721 Clinic Dr, Ste A, 
Tyler, TX 
 (28.0 miles away)
903-592-6152
Languages Spoken:
English
See accepted insurances

Michael Ashigbi is a Hematologist Oncology specialist and a Hematologist in Tyler, Texas. Dr. Ashigbi is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Colorectal Cancer, Anemia, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Bone Marrow Aspiration.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Arielle Lee
Hematology | Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Arielle Lee
Hematology | Oncology
721 Clinic Dr, Ste A, 
Tyler, TX 
 (28.0 miles away)
903-592-6152
Languages Spoken:
English
See accepted insurances

Arielle Lee is a Hematologist and an Oncologist in Tyler, Texas. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lyons's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile